{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:10:26Z","timestamp":1758935426971,"version":"3.44.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.leukres.2009.01.018","type":"journal-article","created":{"date-parts":[[2009,2,22]],"date-time":"2009-02-22T01:27:36Z","timestamp":1235266056000},"page":"937-947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents"],"prefix":"10.1016","volume":"33","author":[{"given":"Cecily A.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda C.","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha N.","family":"Barretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Hemenway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.leukres.2009.01.018_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1101\/gad.1195504","article-title":"Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis","volume":"18","author":"Daser","year":"2004","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.leukres.2009.01.018_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.V96.1.24","article-title":"Biological and therapeutic aspects of infant leukemia","volume":"96","author":"Biondi","year":"2000","journal-title":"Blood"},{"issue":"9321","key":"10.1016\/j.leukres.2009.01.018_bib3","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(02)08782-2","article-title":"Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region","volume":"359","author":"Pui","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.leukres.2009.01.018_bib4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1097-2765(02)00740-2","article-title":"ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation","volume":"10","author":"Nakamura","year":"2002","journal-title":"Mol Cell"},{"issue":"13","key":"10.1016\/j.leukres.2009.01.018_bib5","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1128\/MCB.24.13.5639-5649.2004","article-title":"Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression","volume":"24","author":"Yokoyama","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.leukres.2009.01.018_bib6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1073\/pnas.0408836102","article-title":"Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors","volume":"102","author":"Milne","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.leukres.2009.01.018_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nsmb1128","article-title":"Regulation of MLL1 H3K4 methyltransferase activity by its core components","volume":"13","author":"Dou","year":"2006","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.leukres.2009.01.018_bib8","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.0503072102","article-title":"Global and Hox-specific roles for the MLL1 methyltransferase","volume":"102","author":"Guenther","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.leukres.2009.01.018_bib9","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.leu.2403321","article-title":"Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein","volume":"18","author":"Caslini","year":"2004","journal-title":"Leukemia"},{"issue":"39","key":"10.1016\/j.leukres.2009.01.018_bib10","doi-asserted-by":"crossref","first-page":"14028","DOI":"10.1073\/pnas.0506464102","article-title":"The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression","volume":"102","author":"Xia","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2009.01.018_bib11","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1038\/sj.onc.1210125","article-title":"Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation","volume":"26","author":"Gaussmann","year":"2007","journal-title":"Oncogene"},{"issue":"26","key":"10.1016\/j.leukres.2009.01.018_bib12","doi-asserted-by":"crossref","first-page":"24315","DOI":"10.1074\/jbc.M412237200","article-title":"Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage","volume":"280","author":"Wiederschain","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.leukres.2009.01.018_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"issue":"41","key":"10.1016\/j.leukres.2009.01.018_bib14","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.0503630102","article-title":"MLL associates specifically with a subset of transcriptionally active target genes","volume":"102","author":"Milne","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.leukres.2009.01.018_bib15","first-page":"417","article-title":"Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation","volume":"18","author":"Dell\u2019orto","year":"2007","journal-title":"Oncol Rep"},{"issue":"36","key":"10.1016\/j.leukres.2009.01.018_bib16","doi-asserted-by":"crossref","first-page":"14442","DOI":"10.1073\/pnas.0703211104","article-title":"ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias","volume":"104","author":"Nakanishi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.leukres.2009.01.018_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2141.1997.1522966.x","article-title":"Exon\/intron structure of the human AF-4 gene, a member of the AF-4\/LAF-4\/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukaemia","volume":"98","author":"Nilson","year":"1997","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.leukres.2009.01.018_bib18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1523\/JNEUROSCI.23-05-01631.2003","article-title":"A mutation in Af4 is predicted to cause cerebellar ataxia and cataracts in the robotic mouse","volume":"23","author":"Isaacs","year":"2003","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.leukres.2009.01.018_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood.V96.2.705.014k05_705_710","article-title":"Altered lymphoid development in mice deficient for the mAF4 proto-oncogene","volume":"96","author":"Isnard","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2009.01.018_bib20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/hmg\/ddl444","article-title":"The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling","volume":"16","author":"Bitoun","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"13","key":"10.1016\/j.leukres.2009.01.018_bib21","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2007-05-090514","article-title":"A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification","volume":"110","author":"Mueller","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2009.01.018_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.leu.2403200","article-title":"MLL fusion partners AF4 and AF9 interact at subnuclear foci","volume":"18","author":"Erfurth","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2009.01.018_bib23","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/sj.leu.2403415","article-title":"The synthetic peptide PFWT disrupts AF4\u2013AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells","volume":"18","author":"Srinivasan","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2009.01.018_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.leukres.2007.08.002","article-title":"The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4\u201311 leukemia cells","volume":"32","author":"Palermo","year":"2008","journal-title":"Leukemia Res"},{"issue":"1","key":"10.1016\/j.leukres.2009.01.018_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.11.005","article-title":"Cellular response to etoposide treatment","volume":"252","author":"Montecucco","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2009.01.018_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0268-960X(97)90005-9","article-title":"High-dose cytosine arabinoside in the treatment of acute myeloid leukemia","volume":"11","author":"Cole","year":"1997","journal-title":"Blood Rev"},{"issue":"10","key":"10.1016\/j.leukres.2009.01.018_bib27","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1349-7006.2007.00561.x","article-title":"Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis","volume":"98","author":"Tsutsumi","year":"2007","journal-title":"Cancer Sci"},{"issue":"12","key":"10.1016\/j.leukres.2009.01.018_bib28","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1016\/j.bmcl.2006.03.032","article-title":"Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3","volume":"16","author":"Patch","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.leukres.2009.01.018_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"1","key":"10.1016\/j.leukres.2009.01.018_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-1033.1981.tb06218.x","article-title":"Generalized equations for the analysis of inhibitions of Michaelis\u2013Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors","volume":"115","author":"Chou","year":"1981","journal-title":"Eur J Biochem"},{"issue":"2","key":"10.1016\/j.leukres.2009.01.018_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.leu.2403236","article-title":"Malignant hematopoietic cell lines: in vitro models for the study of MLL gene alterations","volume":"18","author":"Drexler","year":"2004","journal-title":"Leukemia"},{"issue":"1\u20132","key":"10.1016\/j.leukres.2009.01.018_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mrfmmm.2004.11.018","article-title":"The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs","volume":"572","author":"Potter","year":"2005","journal-title":"Mutat Res\/Fundam Mol Mech Mutagen"},{"issue":"10","key":"10.1016\/j.leukres.2009.01.018_bib33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","article-title":"Clinical pharmacokinetics of cytarabine formulations","volume":"41","author":"Hamada","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"10.1016\/j.leukres.2009.01.018_bib34","doi-asserted-by":"crossref","first-page":"10610","DOI":"10.1073\/pnas.91.22.10610","article-title":"11q23 translocations split the \u201cAT-hook\u201d cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene","volume":"91","author":"Zeleznik-Le","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.leukres.2009.01.018_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2141.2007.06700.x","article-title":"FLT3 inhibition in acute myeloid leukaemia","volume":"138","author":"Knapper","year":"2007","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.leukres.2009.01.018_bib36","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-04-2322","article-title":"Phase I pharmacokinetic\u2013pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers","volume":"11","author":"Ramanathan","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.leukres.2009.01.018_bib37","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","article-title":"Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies","volume":"23","author":"Banerji","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.leukres.2009.01.018_bib38","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2009.01.018_bib39","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2009.01.018_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1535-6108(02)00032-6","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling","volume":"1","author":"Yeoh","year":"2002","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.leukres.2009.01.018_bib41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood-2004-01-0388","article-title":"In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects","volume":"104","author":"Levis","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2009.01.018_bib42","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2403881","article-title":"Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway","volume":"19","author":"Yao","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2009.01.018_bib43","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-06-1750","article-title":"Synergism between etoposide and 17AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51","volume":"13","author":"Yao","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.leukres.2009.01.018_bib44","first-page":"4483","article-title":"FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases","volume":"9","author":"Yao","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2009.01.018_bib45","first-page":"197","article-title":"Ara-C: cellular and molecular pharmacology","volume":"72","author":"Grant","year":"1998","journal-title":"Adv Cancer Res"},{"issue":"2","key":"10.1016\/j.leukres.2009.01.018_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1535-6108(03)00003-5","article-title":"Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification","volume":"3","author":"Armstrong","year":"2003","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.leukres.2009.01.018_bib47","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1038\/sj.onc.1210980","article-title":"The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations","volume":"27","author":"Odgerel","year":"2008","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.leukres.2009.01.018_bib48","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1128\/MCB.23.12.4230-4246.2003","article-title":"Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL","volume":"23","author":"Wiederschain","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.leukres.2009.01.018_bib49","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/0008-5472.CAN-04-1356","article-title":"Leukemic stem cells in childhood high-risk ALL\/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19-cells","volume":"65","author":"Hotfilder","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.leukres.2009.01.018_bib50","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood.V82.4.1043.bloodjournal8241043","article-title":"A natural history for pediatric acute leukemia","volume":"82","author":"Greaves","year":"1993","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:56:41Z","timestamp":1758934601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0145212609000216"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.01.018","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2009.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}